1229000-10-5

Basic information

• Product Name: tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate
• Synonyms: tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 3-(1H-benziMidazol-2-yl)-, 1,1-diMethylethyl ester;2-(N-BOC-piperidin-3-yl)-1H-benzoimidazole;tert-butyl 3-(1H-1,3-benzodiazol-2-yl)piperidine-1-carboxylate;3-(Benzimidazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 3-(1H-benzimidazol-2-yl)piperidine-1-carboxylate
• CAS NO: 1229000-10-5
• Molecular Formula: C17H23N3O2
• Molecular Weight: 301.38342
• EINECS: 604-604-1
• Mol File: 1229000-10-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate(1229000-10-5)
• EPA Substance Registry System: tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate(1229000-10-5)

Safety Data

• Hazardous Substances Data: 1229000-10-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate is used as a reactant in the synthesis of piperidinyl benzimidazoles, which are known for their histamine H1 receptor antagonist properties. These compounds are valuable in the development of drugs targeting the central nervous system (CNS) as they exhibit H1-antihistamine activity, making them potential candidates for the treatment of various conditions such as allergies, asthma, and other histamine-mediated disorders.
In the synthesis process, tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate serves as a key intermediate, providing the necessary structural framework for the formation of the final drug molecule. Its unique combination of benzimidazole and piperidine moieties allows for the fine-tuning of the compound's pharmacological properties, such as potency, selectivity, and bioavailability, which are crucial factors in the development of effective therapeutic agents.
Furthermore, the use of tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate in the pharmaceutical industry highlights the importance of chemical diversity and innovation in drug discovery. By exploring novel chemical structures and their potential applications, researchers can identify new therapeutic targets and develop more effective treatments for a wide range of medical conditions.

Upstream product

• 1443057-91-7 tert-butyl 3-((2-aminophenyl)carbamoyl)piperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 95-54-5 1,2-diamino-benzene 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 

Downstream Products

• 1229000-35-4 C₂₅H₃₁N₃O₃ 
• 1229000-36-5 C₂₅H₃₁N₃O₃ 
• 1229000-34-3 C₂₄H₂₈FN₃O₂ 
• 1365884-13-4 2-(piperidin-3-yl)-1H-benzo[d]imidazole hydrochloride 
• 1248737-39-4 C₁₉H₂₀FN₃ 
• 1248722-71-5 C₂₀H₂₃N₃O 

Relevant articles and documents

SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE

The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.

COMPOUNDS AS INHIBITORS OF RENIN

The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to

Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: Identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia

The structure-activity relationships of 2-(piperidin-3-yl)-1H- benzimidazoles, 2-morpholine and 2-thiomorpholin-2-yl-1H-benzimidazoles are described. In the lead optimization process, the pKa and/or log P of benzimidazole analogs were reduced e

The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia

A series of 2-(3-aminopiperidine)-benzimidazoles were identified as selective H1-antihistamines for evaluation as potential sedative hypnotics. Representative compounds showed improved hERG selectivity over a previously identified 2-aminobenzimidazole series. While hERG activity could be modulated via manipulation of the benzimidazole N1 substituent, this approach led to a reduction in CNS exposure for the more selective compounds. One example, 9q, retained a suitable selectivity profile with CNS exposure equivalent to known centrally active H1-antihistamines.